Professors from Harvard Medical School and the Georgia State University College of Law published in The New England Journal of Medicine (NEJM) a critique of the Trump Administration’s proposed Regulatory Accountability Act of 2017. They assert that “the proposed law would increase uncertainty for the health care industry and diminish” FDA’s ability to protect the public health.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
